Osteoporosis: study proposes another benchmark for monitoring oral bisphosphonates

Two ways to define a treatment response

Standard monitoring involves checking whether a change in a measurement exceeds the least significant change. This threshold helps distinguish a measurable change from measurement noise. According to the authors, this approach assumes that bone mineral density would remain stable without treatment.

Instead, they propose an “expected change,” defined using the response observed in patients who actually take their treatment. The selected threshold corresponds to a change exceeded by 90% of adherent patients. The aim is therefore to compare the response with what is expected during treatment, rather than with measurement variability alone.

A comparison involving 108 postmenopausal women

The study involved 108 postmenopausal women under 85 years of age, randomly assigned to one of three oral bisphosphonates: alendronate, ibandronate or risedronate. They were treated for two years at approved doses, with calcium and vitamin D supplementation.

The researchers examined changes in bone mineral density at the lumbar spine and hip at 24 months, as well as changes in CTX and PINP at three months. These markers provide information about bone turnover. The comparison therefore involves different types of measurements taken at different time points.

Markers that detect a change more often

The proportion of women whose change exceeded the conventional threshold was 47% for lumbar spine density and 24% for hip density. It reached 96% for CTX and 94% for PINP. The markers also had a better signal-to-noise ratio.

With the new method, the expected change exceeded the least significant change threshold for CTX and PINP, but not for either bone density measurement. These findings support their usefulness for detecting a biological response to treatment in this population.

A monitoring tool, not proof of protection against fractures

The abstract does not report a comparison of fractures by monitoring strategy. Nor does it establish that a single result could reliably identify poor adherence or justify a change in treatment.

The study proposes a promising biological benchmark, but its validation in other populations and its usefulness for guiding clinical decisions remain to be established.

What we can take away

CTX and PINP appear better at detecting a biological response to oral bisphosphonates than changes in bone density in this study. The clinical value of the new “expected change” threshold remains to be confirmed.